Can-Fite BioPharma Ltd. (CANF) 10-Year Financial Performance & Capital Metrics

CANF •

HealthcareBiotechnologyImmunology and Inflammation Therapies

AboutCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Show more

Revenue $674K -9.3%
EBITDA -$8M +0.7%
Net Income -$8M -3.2%
EPS (Diluted) -1.08 +40.0%
Gross Margin 100%
EBITDA Margin -1205.19% -9.5%
Operating Margin -1206.23% -9.4%
Net Margin -1169.14% -13.8%
ROE -134.94% +5.3%
ROIC -448.35% -29.9%
Debt/Equity 0.02 +198.6%
Interest Coverage -580.71 +0.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 99 (top 1%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Sales declining 19.8% over 5 years
✗Shares diluted 70.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-19.81%

3Y-7.55%

TTM-16.04%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-19.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.17%

ROCE

10Y Avg-119.67%

5Y Avg-123.38%

3Y Avg-100.78%

Latest-108.13%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	164.72K	169.5K	844.75K	3.82M	2.03M	763K	853K	810K	743K	674K
Revenue Growth %	-	2.9%	398.38%	352.21%	-46.81%	-62.45%	11.8%	-5.04%	-8.27%	-9.29%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	164.72K	169.5K	844.75K	3.82M	2.03M	763K	853K	810K	743K	674K
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Gross Profit Growth %	-	2.9%	398.38%	352.21%	-46.81%	-62.45%	11.8%	-5.04%	-8.27%	-9.29%
Operating Expenses+	6.58M	8.8M	8.22M	9.23M	14.04M	14.9M	13.7M	10.91M	8.94M	8.8M
OpEx % of Revenue	3994.56%	5193.72%	973.13%	241.73%	690.9%	1953.08%	1605.51%	1346.42%	1202.96%	1306.23%
Selling, General & Admin	2.7M	2.7M	2.95M	3.16M	3.06M	2.95M	3.85M	3.14M	2.96M	3.05M
SG&A % of Revenue	1639.04%	1590.8%	349.08%	82.7%	150.74%	386.76%	450.76%	388.02%	397.71%	452.08%
Research & Development	3.86M	6.08M	5.27M	6.08M	10.98M	11.95M	9.85M	7.76M	5.98M	5.76M
R&D % of Revenue	2340.9%	3585.9%	624.05%	159.03%	540.16%	1566.32%	1154.75%	958.4%	805.25%	854.15%
Other Operating Expenses	24.08K	28.86K	31.07K	0	0	0	0	0	0	0
Operating Income+	-6.42M	-8.63M	-7.38M	-5.41M	-12.01M	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
Operating Margin %	-3894.56%	-5093.72%	-873.13%	-141.73%	-590.9%	-1853.08%	-1505.51%	-1246.42%	-1102.96%	-1206.23%
Operating Income Growth %	10.06%	-34.59%	14.57%	26.6%	-121.78%	-17.76%	9.17%	21.38%	18.83%	0.79%
EBITDA+	-6.4M	-8.62M	-7.36M	-5.4M	-11.99M	-14.13M	-12.83M	-10.08M	-8.18M	-8.12M
EBITDA Margin %	-3884.61%	-5082.83%	-870.78%	-141.36%	-590.21%	-1851.51%	-1503.87%	-1244.69%	-1100.94%	-1205.19%
EBITDA Growth %	10.14%	-34.64%	14.62%	26.59%	-122.09%	-17.79%	9.2%	21.41%	18.87%	0.7%
D&A (Non-Cash Add-back)	16.39K	18.46K	19.85K	14K	14K	12K	14K	14K	15K	7K
EBIT	-6.42M	-8.36M	-6.4M	-6.14M	-12.01M	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
Net Interest Income+	1.35M	61.74K	41K	33K	-376K	-343K	6K	206K	492K	277K
Interest Income	1.92M	89.09K	69K	51K	72K	44K	24K	222K	506K	291K
Interest Expense	564.34K	27.35K	28K	18K	448K	387K	18K	16K	14K	14K
Other Income/Expense	1.35M	269.86K	781K	-1.15M	-618K	-304K	227K	-77K	561K	250K
Pretax Income+	-5.06M	-6.99M	-4.95M	-6.57M	-12.63M	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Pretax Margin %	-3072.01%	-4125.31%	-586.07%	-171.91%	-621.31%	-1892.92%	-1478.9%	-1255.93%	-1027.46%	-1169.14%
Income Tax+	4.36K	29.12K	29.92K	4K	0	0	0	0	0	0
Effective Tax Rate %	94.8%	98.64%	100.36%	100.06%	100%	100%	99.84%	100%	100%	100%
Net Income+	-4.8M	-6.9M	-4.97M	-6.57M	-12.63M	-14.44M	-12.6M	-10.17M	-7.63M	-7.88M
Net Margin %	-2912.29%	-4069.33%	-588.18%	-172.02%	-621.31%	-1892.92%	-1476.55%	-1255.93%	-1027.46%	-1169.14%
Net Income Growth %	21.38%	-43.79%	27.96%	-32.25%	-92.13%	-14.4%	12.8%	19.23%	24.96%	-3.22%
Net Income (Continuing)	-5.06M	-8.39M	-6.43M	-6.57M	-12.63M	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	129.11K	8.58K	0	0	0	0	0	0	0	0
EPS (Diluted)+	-81.00	-90.00	-57.00	-51.00	-45.00	-12.69	-8.25	-3.75	-1.80	-1.08
EPS Growth %	22.86%	-11.11%	36.67%	10.53%	11.76%	71.8%	34.99%	54.55%	52%	40%
EPS (Basic)	-81.00	-90.00	-57.00	-51.00	-45.00	-12.69	-9.00	-3.75	-1.80	-1.08
Diluted Shares Outstanding	76.51K	92.31K	108.42K	129.67K	286.37K	1.19M	1.84M	2.72M	4.26M	7.25M
Basic Shares Outstanding	76.51K	92.31K	108.42K	129.67K	286.37K	1.14M	1.53M	2.72M	4.26M	7.25M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.53M	10.1M	6.87M	7.9M	7.14M	9.4M	20.07M	9.16M	9.91M	8.98M
Cash & Short-Term Investments	16.91M	8.11M	3.5M	3.89M	2.76M	8.34M	19.14M	7.98M	8.92M	7.89M
Cash Only	16.91M	8.11M	3.5M	3.62M	2.7M	8.27M	4.39M	2.98M	4.28M	4.83M
Short-Term Investments	0	0	0	273K	64K	75K	14.75M	5M	4.64M	3.06M
Accounts Receivable	61.99K	21.84K	0	0	637K	18K	48K	47K	78K	77K
Days Sales Outstanding	137.37	47.02	-	-	114.42	8.61	20.54	21.18	38.32	41.7
Inventory	-620.81K	0	-3.3M	0	-715K	0	-48K	-39K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	558.82K	0	0	41K	729K	0	48K	47K	0	1.02M
Total Non-Current Assets+	67.37K	62.91K	965.88K	49K	1.03M	123K	185K	126K	81K	138K
Property, Plant & Equipment	60.46K	53.29K	46.03K	47K	118K	123K	185K	126K	81K	138K
Fixed Asset Turnover	2.72x	3.18x	18.35x	81.28x	17.22x	6.20x	4.61x	6.43x	9.17x	4.88x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	914.66K	0	0	0	0	8K	0	0
Other Non-Current Assets	6.92K	9.62K	5.18K	2K	912K	0	0	-8K	0	0
Total Assets+	17.6M	10.17M	7.83M	7.95M	8.17M	9.52M	20.25M	9.28M	9.99M	9.12M
Asset Turnover	0.01x	0.02x	0.11x	0.48x	0.25x	0.08x	0.04x	0.09x	0.07x	0.07x
Asset Growth %	72.78%	-42.24%	-22.96%	1.53%	2.79%	16.5%	112.67%	-54.16%	7.61%	-8.7%
Total Current Liabilities+	1.78M	2.5M	1.8M	3.12M	3.27M	1.27M	2.73M	2.5M	2.02M	2.05M
Accounts Payable	461.87K	1.25M	427K	1.07M	2.16M	561K	954K	896K	427K	618K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	43K	53K	48K	27K	53K
Deferred Revenue (Current)	219.54K	321.58K	373.75K	926K	469K	334K	818K	783K	622K	405K
Other Current Liabilities	149.35K	669K	268.39K	149K	165K	53K	550K	444K	667K	622K
Current Ratio	9.86x	4.04x	3.82x	2.53x	2.18x	7.41x	7.35x	3.66x	4.90x	4.38x
Quick Ratio	10.21x	4.04x	5.66x	2.53x	2.40x	7.41x	7.37x	3.68x	4.90x	4.38x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.38M	3.79M	2.98M	1.82M	2.46M	2.18M	3.14M	2.31M	1.73M	1.63M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	39K	24K	71K	14K	13K	51K
Deferred Tax Liabilities	0	0	0	0	-2.42M	-2.16M	-3.07M	-2.29M	0	0
Other Non-Current Liabilities	4.45M	2.62M	2.14M	0	1.57M	2.16M	3.07M	2.29M	0	0
Total Liabilities	7.16M	6.29M	4.78M	4.94M	5.73M	3.45M	5.87M	4.81M	3.75M	3.68M
Total Debt+	0	0	0	0	75K	67K	124K	62K	40K	104K
Net Debt	-16.91M	-8.11M	-3.5M	-3.62M	-2.62M	-8.2M	-4.27M	-2.92M	-4.24M	-4.72M
Debt / Equity	-	-	-	-	0.03x	0.01x	0.01x	0.01x	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.37x	-315.66x	-263.42x	-300.78x	-26.80x	-36.53x	-713.44x	-631.04x	-585.36x	-580.71x
Total Equity+	10.44M	3.87M	3.05M	3.02M	2.44M	6.07M	14.38M	4.47M	6.24M	5.44M
Equity Growth %	52.33%	-62.91%	-21.17%	-1.27%	-19%	148.73%	136.78%	-68.91%	39.6%	-12.93%
Book Value per Share	136.52	41.97	28.17	23.25	8.53	5.08	7.80	1.64	1.47	0.75
Total Shareholders' Equity	10.32M	3.87M	3.05M	3.02M	2.44M	6.07M	14.38M	4.47M	6.24M	5.44M
Common Stock	1.8M	1.83M	2.39M	2.63M	8.22M	33.04M	60.65M	0	0	0
Retained Earnings	-82.71M	-90.98M	-105.66M	-100.62M	-110.31M	-125.47M	-140.67M	-150.85M	-158.48M	-166.36M
Treasury Stock	-929.38K	-943.17K	0	0	0	0	0	0	0	0
Accumulated OCI	4.58M	5.08M	6.28M	6.93M	1.13M	1.13M	1.13M	1.13M	1.13M	1.13M
Minority Interest	129.11K	8.58K	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.65M	-8.93M	-9.52M	-4.16M	-10.83M	-12.06M	-9.86M	-10.8M	-8.44M	-7.64M
Operating CF Margin %	-2824.11%	-5266.88%	-1127.35%	-108.77%	-533.17%	-1581%	-1155.69%	-1333.46%	-1135.94%	-1133.09%
Operating CF Growth %	36.51%	-91.91%	-6.67%	56.37%	-160.75%	-11.34%	18.28%	-9.57%	21.86%	9.51%
Net Income	-5.06M	-7.02M	-4.98M	-6.57M	-12.63M	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Depreciation & Amortization	16.39K	18.46K	19.85K	14K	14K	12K	14K	14K	15K	7K
Stock-Based Compensation	109K	309K	195.07K	535K	385K	355K	466K	263K	261K	362K
Deferred Taxes	0	0	278.51K	0	212K	11K	-94K	0	0	0
Other Non-Cash Items	-1.09M	-1.47M	-2.59M	733K	-5K	1K	-59K	396K	-139K	141K
Working Capital Changes	1.49M	-449.49K	-2.45M	1.13M	1.19M	2M	2.43M	-1.3M	-943K	-267K
Change in Receivables	255.15K	-1.37M	-1.16M	-853K	270K	2.73M	0	0	0	0
Change in Inventory	0	0	0	125K	-316K	1.27M	0	0	0	0
Change in Payables	78.9K	591.95K	-964.15K	644K	1.08M	-1.59M	393K	-58K	-469K	191K
Cash from Investing+	-42.78K	-10.4K	-29.64K	-33K	-253K	-26K	-14.51M	9.5M	498K	1.5M
Capital Expenditures	-45.34K	-10.4K	-6.91K	-33K	-3K	-26K	-11K	-9K	-2K	-5K
CapEx % of Revenue	27.53%	6.13%	0.82%	0.86%	0.15%	3.41%	1.29%	1.11%	0.27%	0.74%
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.56K	0	-22K	0	-250K	0	0	9.51M	500K	1.5M
Cash from Financing+	12.38M	0	4.88M	4.39M	10.17M	17.68M	20.46M	0	9.14M	6.71M
Debt Issued (Net)	0	0	0	0	-34K	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	1000K	1000K	1000K	1000K	0	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	0	0	0	0	34K	0	0	0	0	0
Net Change in Cash	7.67M	-9.05M	-5.48M	110K	-918K	5.57M	-3.88M	-1.41M	1.3M	547K
Free Cash Flow+	-4.7M	-8.94M	-9.53M	-4.19M	-10.84M	-12.09M	-9.87M	-10.81M	-8.44M	-7.64M
FCF Margin %	-2851.64%	-5273.02%	-1128.17%	-109.63%	-533.32%	-1584.4%	-1156.98%	-1334.57%	-1136.2%	-1133.83%
FCF Growth %	35.98%	-90.28%	-6.63%	56.06%	-158.76%	-11.55%	18.36%	-9.53%	21.91%	9.48%
FCF per Share	-61.39	-96.83	-87.90	-32.30	-37.84	-10.12	-5.35	-3.98	-1.98	-1.05
FCF Conversion (FCF/Net Income)	0.97x	1.29x	1.92x	0.63x	0.86x	0.84x	0.78x	1.06x	1.11x	0.97x
Interest Paid	0	0	23K	18K	0	0	0	0	0	0
Taxes Paid	4.1K	29K	29K	4K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-55.45%	-96.34%	-143.44%	-216.55%	-462.71%	-339.2%	-123.14%	-107.91%	-142.49%	-134.94%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-241.12%	-129.75%	-345.2%	-448.35%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	-2912.29%	-4069.33%	-588.18%	-172.02%	-621.31%	-1892.92%	-1476.55%	-1255.93%	-1027.46%	-1169.14%
Debt / Equity	-	-	-	-	0.03x	0.01x	0.01x	0.01x	0.01x	0.02x
Interest Coverage	-11.37x	-315.66x	-263.42x	-300.78x	-26.80x	-36.53x	-713.44x	-631.04x	-585.36x	-580.71x
FCF Conversion	0.97x	1.29x	1.92x	0.63x	0.86x	0.84x	0.78x	1.06x	1.11x	0.97x
Revenue Growth	-	2.9%	398.38%	352.21%	-46.81%	-62.45%	11.8%	-5.04%	-8.27%	-9.29%

US Stock Screener

...

Can-Fite BioPharma Ltd. (CANF) 10-Year Financial Performance & Capital Metrics

CANF •

HealthcareBiotechnologyImmunology and Inflammation Therapies

Revenue $674K -9.3%
EBITDA -$8M +0.7%
Net Income -$8M -3.2%
EPS (Diluted) -1.08 +40.0%
Gross Margin 100%
EBITDA Margin -1205.19% -9.5%
Operating Margin -1206.23% -9.4%
Net Margin -1169.14% -13.8%
ROE -134.94% +5.3%
ROIC -448.35% -29.9%
Debt/Equity 0.02 +198.6%
Interest Coverage -580.71 +0.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 99 (top 1%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Sales declining 19.8% over 5 years
✗Shares diluted 70.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-19.81%

3Y-7.55%

TTM-16.04%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-19.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.17%

ROCE

10Y Avg-119.67%

5Y Avg-123.38%

3Y Avg-100.78%

Latest-108.13%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	164.72K	169.5K	844.75K	3.82M	2.03M	763K	853K	810K	743K	674K
Revenue Growth %	-	2.9%	398.38%	352.21%	-46.81%	-62.45%	11.8%	-5.04%	-8.27%	-9.29%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	164.72K	169.5K	844.75K	3.82M	2.03M	763K	853K	810K	743K	674K
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Gross Profit Growth %	-	2.9%	398.38%	352.21%	-46.81%	-62.45%	11.8%	-5.04%	-8.27%	-9.29%
Operating Expenses+	6.58M	8.8M	8.22M	9.23M	14.04M	14.9M	13.7M	10.91M	8.94M	8.8M
OpEx % of Revenue	3994.56%	5193.72%	973.13%	241.73%	690.9%	1953.08%	1605.51%	1346.42%	1202.96%	1306.23%
Selling, General & Admin	2.7M	2.7M	2.95M	3.16M	3.06M	2.95M	3.85M	3.14M	2.96M	3.05M
SG&A % of Revenue	1639.04%	1590.8%	349.08%	82.7%	150.74%	386.76%	450.76%	388.02%	397.71%	452.08%
Research & Development	3.86M	6.08M	5.27M	6.08M	10.98M	11.95M	9.85M	7.76M	5.98M	5.76M
R&D % of Revenue	2340.9%	3585.9%	624.05%	159.03%	540.16%	1566.32%	1154.75%	958.4%	805.25%	854.15%
Other Operating Expenses	24.08K	28.86K	31.07K	0	0	0	0	0	0	0
Operating Income+	-6.42M	-8.63M	-7.38M	-5.41M	-12.01M	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
Operating Margin %	-3894.56%	-5093.72%	-873.13%	-141.73%	-590.9%	-1853.08%	-1505.51%	-1246.42%	-1102.96%	-1206.23%
Operating Income Growth %	10.06%	-34.59%	14.57%	26.6%	-121.78%	-17.76%	9.17%	21.38%	18.83%	0.79%
EBITDA+	-6.4M	-8.62M	-7.36M	-5.4M	-11.99M	-14.13M	-12.83M	-10.08M	-8.18M	-8.12M
EBITDA Margin %	-3884.61%	-5082.83%	-870.78%	-141.36%	-590.21%	-1851.51%	-1503.87%	-1244.69%	-1100.94%	-1205.19%
EBITDA Growth %	10.14%	-34.64%	14.62%	26.59%	-122.09%	-17.79%	9.2%	21.41%	18.87%	0.7%
D&A (Non-Cash Add-back)	16.39K	18.46K	19.85K	14K	14K	12K	14K	14K	15K	7K
EBIT	-6.42M	-8.36M	-6.4M	-6.14M	-12.01M	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
Net Interest Income+	1.35M	61.74K	41K	33K	-376K	-343K	6K	206K	492K	277K
Interest Income	1.92M	89.09K	69K	51K	72K	44K	24K	222K	506K	291K
Interest Expense	564.34K	27.35K	28K	18K	448K	387K	18K	16K	14K	14K
Other Income/Expense	1.35M	269.86K	781K	-1.15M	-618K	-304K	227K	-77K	561K	250K
Pretax Income+	-5.06M	-6.99M	-4.95M	-6.57M	-12.63M	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Pretax Margin %	-3072.01%	-4125.31%	-586.07%	-171.91%	-621.31%	-1892.92%	-1478.9%	-1255.93%	-1027.46%	-1169.14%
Income Tax+	4.36K	29.12K	29.92K	4K	0	0	0	0	0	0
Effective Tax Rate %	94.8%	98.64%	100.36%	100.06%	100%	100%	99.84%	100%	100%	100%
Net Income+	-4.8M	-6.9M	-4.97M	-6.57M	-12.63M	-14.44M	-12.6M	-10.17M	-7.63M	-7.88M
Net Margin %	-2912.29%	-4069.33%	-588.18%	-172.02%	-621.31%	-1892.92%	-1476.55%	-1255.93%	-1027.46%	-1169.14%
Net Income Growth %	21.38%	-43.79%	27.96%	-32.25%	-92.13%	-14.4%	12.8%	19.23%	24.96%	-3.22%
Net Income (Continuing)	-5.06M	-8.39M	-6.43M	-6.57M	-12.63M	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	129.11K	8.58K	0	0	0	0	0	0	0	0
EPS (Diluted)+	-81.00	-90.00	-57.00	-51.00	-45.00	-12.69	-8.25	-3.75	-1.80	-1.08
EPS Growth %	22.86%	-11.11%	36.67%	10.53%	11.76%	71.8%	34.99%	54.55%	52%	40%
EPS (Basic)	-81.00	-90.00	-57.00	-51.00	-45.00	-12.69	-9.00	-3.75	-1.80	-1.08
Diluted Shares Outstanding	76.51K	92.31K	108.42K	129.67K	286.37K	1.19M	1.84M	2.72M	4.26M	7.25M
Basic Shares Outstanding	76.51K	92.31K	108.42K	129.67K	286.37K	1.14M	1.53M	2.72M	4.26M	7.25M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.53M	10.1M	6.87M	7.9M	7.14M	9.4M	20.07M	9.16M	9.91M	8.98M
Cash & Short-Term Investments	16.91M	8.11M	3.5M	3.89M	2.76M	8.34M	19.14M	7.98M	8.92M	7.89M
Cash Only	16.91M	8.11M	3.5M	3.62M	2.7M	8.27M	4.39M	2.98M	4.28M	4.83M
Short-Term Investments	0	0	0	273K	64K	75K	14.75M	5M	4.64M	3.06M
Accounts Receivable	61.99K	21.84K	0	0	637K	18K	48K	47K	78K	77K
Days Sales Outstanding	137.37	47.02	-	-	114.42	8.61	20.54	21.18	38.32	41.7
Inventory	-620.81K	0	-3.3M	0	-715K	0	-48K	-39K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	558.82K	0	0	41K	729K	0	48K	47K	0	1.02M
Total Non-Current Assets+	67.37K	62.91K	965.88K	49K	1.03M	123K	185K	126K	81K	138K
Property, Plant & Equipment	60.46K	53.29K	46.03K	47K	118K	123K	185K	126K	81K	138K
Fixed Asset Turnover	2.72x	3.18x	18.35x	81.28x	17.22x	6.20x	4.61x	6.43x	9.17x	4.88x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	914.66K	0	0	0	0	8K	0	0
Other Non-Current Assets	6.92K	9.62K	5.18K	2K	912K	0	0	-8K	0	0
Total Assets+	17.6M	10.17M	7.83M	7.95M	8.17M	9.52M	20.25M	9.28M	9.99M	9.12M
Asset Turnover	0.01x	0.02x	0.11x	0.48x	0.25x	0.08x	0.04x	0.09x	0.07x	0.07x
Asset Growth %	72.78%	-42.24%	-22.96%	1.53%	2.79%	16.5%	112.67%	-54.16%	7.61%	-8.7%
Total Current Liabilities+	1.78M	2.5M	1.8M	3.12M	3.27M	1.27M	2.73M	2.5M	2.02M	2.05M
Accounts Payable	461.87K	1.25M	427K	1.07M	2.16M	561K	954K	896K	427K	618K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	43K	53K	48K	27K	53K
Deferred Revenue (Current)	219.54K	321.58K	373.75K	926K	469K	334K	818K	783K	622K	405K
Other Current Liabilities	149.35K	669K	268.39K	149K	165K	53K	550K	444K	667K	622K
Current Ratio	9.86x	4.04x	3.82x	2.53x	2.18x	7.41x	7.35x	3.66x	4.90x	4.38x
Quick Ratio	10.21x	4.04x	5.66x	2.53x	2.40x	7.41x	7.37x	3.68x	4.90x	4.38x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.38M	3.79M	2.98M	1.82M	2.46M	2.18M	3.14M	2.31M	1.73M	1.63M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	39K	24K	71K	14K	13K	51K
Deferred Tax Liabilities	0	0	0	0	-2.42M	-2.16M	-3.07M	-2.29M	0	0
Other Non-Current Liabilities	4.45M	2.62M	2.14M	0	1.57M	2.16M	3.07M	2.29M	0	0
Total Liabilities	7.16M	6.29M	4.78M	4.94M	5.73M	3.45M	5.87M	4.81M	3.75M	3.68M
Total Debt+	0	0	0	0	75K	67K	124K	62K	40K	104K
Net Debt	-16.91M	-8.11M	-3.5M	-3.62M	-2.62M	-8.2M	-4.27M	-2.92M	-4.24M	-4.72M
Debt / Equity	-	-	-	-	0.03x	0.01x	0.01x	0.01x	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.37x	-315.66x	-263.42x	-300.78x	-26.80x	-36.53x	-713.44x	-631.04x	-585.36x	-580.71x
Total Equity+	10.44M	3.87M	3.05M	3.02M	2.44M	6.07M	14.38M	4.47M	6.24M	5.44M
Equity Growth %	52.33%	-62.91%	-21.17%	-1.27%	-19%	148.73%	136.78%	-68.91%	39.6%	-12.93%
Book Value per Share	136.52	41.97	28.17	23.25	8.53	5.08	7.80	1.64	1.47	0.75
Total Shareholders' Equity	10.32M	3.87M	3.05M	3.02M	2.44M	6.07M	14.38M	4.47M	6.24M	5.44M
Common Stock	1.8M	1.83M	2.39M	2.63M	8.22M	33.04M	60.65M	0	0	0
Retained Earnings	-82.71M	-90.98M	-105.66M	-100.62M	-110.31M	-125.47M	-140.67M	-150.85M	-158.48M	-166.36M
Treasury Stock	-929.38K	-943.17K	0	0	0	0	0	0	0	0
Accumulated OCI	4.58M	5.08M	6.28M	6.93M	1.13M	1.13M	1.13M	1.13M	1.13M	1.13M
Minority Interest	129.11K	8.58K	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.65M	-8.93M	-9.52M	-4.16M	-10.83M	-12.06M	-9.86M	-10.8M	-8.44M	-7.64M
Operating CF Margin %	-2824.11%	-5266.88%	-1127.35%	-108.77%	-533.17%	-1581%	-1155.69%	-1333.46%	-1135.94%	-1133.09%
Operating CF Growth %	36.51%	-91.91%	-6.67%	56.37%	-160.75%	-11.34%	18.28%	-9.57%	21.86%	9.51%
Net Income	-5.06M	-7.02M	-4.98M	-6.57M	-12.63M	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Depreciation & Amortization	16.39K	18.46K	19.85K	14K	14K	12K	14K	14K	15K	7K
Stock-Based Compensation	109K	309K	195.07K	535K	385K	355K	466K	263K	261K	362K
Deferred Taxes	0	0	278.51K	0	212K	11K	-94K	0	0	0
Other Non-Cash Items	-1.09M	-1.47M	-2.59M	733K	-5K	1K	-59K	396K	-139K	141K
Working Capital Changes	1.49M	-449.49K	-2.45M	1.13M	1.19M	2M	2.43M	-1.3M	-943K	-267K
Change in Receivables	255.15K	-1.37M	-1.16M	-853K	270K	2.73M	0	0	0	0
Change in Inventory	0	0	0	125K	-316K	1.27M	0	0	0	0
Change in Payables	78.9K	591.95K	-964.15K	644K	1.08M	-1.59M	393K	-58K	-469K	191K
Cash from Investing+	-42.78K	-10.4K	-29.64K	-33K	-253K	-26K	-14.51M	9.5M	498K	1.5M
Capital Expenditures	-45.34K	-10.4K	-6.91K	-33K	-3K	-26K	-11K	-9K	-2K	-5K
CapEx % of Revenue	27.53%	6.13%	0.82%	0.86%	0.15%	3.41%	1.29%	1.11%	0.27%	0.74%
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.56K	0	-22K	0	-250K	0	0	9.51M	500K	1.5M
Cash from Financing+	12.38M	0	4.88M	4.39M	10.17M	17.68M	20.46M	0	9.14M	6.71M
Debt Issued (Net)	0	0	0	0	-34K	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	1000K	1000K	1000K	1000K	0	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	0	0	0	0	34K	0	0	0	0	0
Net Change in Cash	7.67M	-9.05M	-5.48M	110K	-918K	5.57M	-3.88M	-1.41M	1.3M	547K
Free Cash Flow+	-4.7M	-8.94M	-9.53M	-4.19M	-10.84M	-12.09M	-9.87M	-10.81M	-8.44M	-7.64M
FCF Margin %	-2851.64%	-5273.02%	-1128.17%	-109.63%	-533.32%	-1584.4%	-1156.98%	-1334.57%	-1136.2%	-1133.83%
FCF Growth %	35.98%	-90.28%	-6.63%	56.06%	-158.76%	-11.55%	18.36%	-9.53%	21.91%	9.48%
FCF per Share	-61.39	-96.83	-87.90	-32.30	-37.84	-10.12	-5.35	-3.98	-1.98	-1.05
FCF Conversion (FCF/Net Income)	0.97x	1.29x	1.92x	0.63x	0.86x	0.84x	0.78x	1.06x	1.11x	0.97x
Interest Paid	0	0	23K	18K	0	0	0	0	0	0
Taxes Paid	4.1K	29K	29K	4K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-55.45%	-96.34%	-143.44%	-216.55%	-462.71%	-339.2%	-123.14%	-107.91%	-142.49%	-134.94%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-241.12%	-129.75%	-345.2%	-448.35%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	-2912.29%	-4069.33%	-588.18%	-172.02%	-621.31%	-1892.92%	-1476.55%	-1255.93%	-1027.46%	-1169.14%
Debt / Equity	-	-	-	-	0.03x	0.01x	0.01x	0.01x	0.01x	0.02x
Interest Coverage	-11.37x	-315.66x	-263.42x	-300.78x	-26.80x	-36.53x	-713.44x	-631.04x	-585.36x	-580.71x
FCF Conversion	0.97x	1.29x	1.92x	0.63x	0.86x	0.84x	0.78x	1.06x	1.11x	0.97x
Revenue Growth	-	2.9%	398.38%	352.21%	-46.81%	-62.45%	11.8%	-5.04%	-8.27%	-9.29%

Can-Fite BioPharma Ltd. (CANF) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CANF vs Peers

vs ARGX

vs AKTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Can-Fite BioPharma Ltd. (CANF) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CANF vs Peers

vs ARGX

vs AKTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios